HTLV-1: A Potential Cure to an "Incurable Disease"

Innovar, L.L.C. is proud to announce issuance of US 10702567 which is directed to the treatment of HTLV-1 infection. Even though a cure for HTLV-1 infection is not yet commercially available, #Phoenix #Biotechnology (San Antonio, TX, www.PhoenixBiotechnology.com) has patented a potential cure for HTLV-1, which predominately infects CD4+ T-lymphocytes and causes adult T-cell leukemia/lymphoma #ATLLL) –a rare, yet aggressive hematological malignancy with high rates of therapy-resistance and generally poor clinical outcomes, in addition to several #autoimmune/#inflammatory conditions, including #infectious #dermatitis, #rheumatoid #arthritis, #uveitis, #keratoconjunctivitis, #sicca #syndrome, #Sjögren’s syndrome, and #HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis).